JP2018511634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511634A5 JP2018511634A5 JP2017553956A JP2017553956A JP2018511634A5 JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5 JP 2017553956 A JP2017553956 A JP 2017553956A JP 2017553956 A JP2017553956 A JP 2017553956A JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- cancer
- dihydro
- solvent
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021009106A JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015076639 | 2015-04-15 | ||
| CNPCT/CN2015/076639 | 2015-04-15 | ||
| PCT/CN2016/079251 WO2016165626A1 (en) | 2015-04-15 | 2016-04-14 | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009106A Division JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511634A JP2018511634A (ja) | 2018-04-26 |
| JP2018511634A5 true JP2018511634A5 (cg-RX-API-DMAC7.html) | 2019-05-23 |
| JP7320741B2 JP7320741B2 (ja) | 2023-08-04 |
Family
ID=57125563
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553956A Active JP7320741B2 (ja) | 2015-04-15 | 2016-04-14 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2021009106A Active JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A Withdrawn JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009106A Active JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A Withdrawn JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10351559B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3283486B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7320741B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240049684A (cg-RX-API-DMAC7.html) |
| CN (2) | CN107531682B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016248376B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2981746C (cg-RX-API-DMAC7.html) |
| EA (1) | EA035680B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL255555B (cg-RX-API-DMAC7.html) |
| MX (1) | MX381053B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ735715A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201707984TA (cg-RX-API-DMAC7.html) |
| TW (4) | TWI792406B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016165626A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201706392B (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2609659C (en) | 2005-05-26 | 2014-01-28 | Neuron Systems, Inc. | Azanaphthalenes, compositions and methods for treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN103596926B (zh) | 2011-12-31 | 2015-11-25 | 百济神州有限公司 | 作为raf激酶抑制剂的稠合三环化合物 |
| AU2014209387B2 (en) | 2013-01-23 | 2018-11-01 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| EP3283486B1 (en) | 2015-04-15 | 2022-07-27 | BeiGene, Ltd. | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| EP4400106A1 (en) | 2015-08-21 | 2024-07-17 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| AU2017293423B2 (en) | 2016-07-05 | 2023-05-25 | Beone Medicines I Gmbh | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| DK3618875T3 (da) | 2017-05-02 | 2023-07-10 | Novartis Ag | Kombinationsterapi omfattende en raf-inhibitor og trametinib |
| WO2019075136A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MY202547A (en) * | 2018-10-31 | 2024-05-07 | Servier Lab | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same |
| CN116715662A (zh) * | 2019-01-25 | 2023-09-08 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
| CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
| MX2021010829A (es) * | 2019-03-15 | 2021-12-10 | Forma Therapeutics Inc | Inhibición de la proteína de unión al elemento de respuesta a adenosín monofosfato (amp) cíclica (creb). |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| KR102881316B1 (ko) | 2019-05-13 | 2025-11-05 | 노파르티스 아게 | 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태 |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| PE20231211A1 (es) * | 2020-04-03 | 2023-08-17 | Springworks Therapeutics Inc | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres |
| CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
| JP2025519981A (ja) * | 2022-06-08 | 2025-06-30 | マップキュア，エルエルシー | Ｂ－ｒａｆ阻害剤によるがんの治療方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| CN101365682A (zh) * | 2005-12-08 | 2009-02-11 | 千禧药品公司 | 具有激酶抑制活性的双环化合物 |
| EP2021327B1 (en) | 2006-05-15 | 2012-04-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2008023239A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| WO2008030448A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
| AU2008247500A1 (en) | 2007-05-04 | 2008-11-13 | Irm Llc | Compounds and compositions as c-kit and PDGFR kinase inhibitors |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| CN103596926B (zh) | 2011-12-31 | 2015-11-25 | 百济神州有限公司 | 作为raf激酶抑制剂的稠合三环化合物 |
| EP3283486B1 (en) | 2015-04-15 | 2022-07-27 | BeiGene, Ltd. | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
-
2016
- 2016-04-14 EP EP16779601.0A patent/EP3283486B1/en active Active
- 2016-04-14 TW TW110125410A patent/TWI792406B/zh active
- 2016-04-14 US US15/565,807 patent/US10351559B2/en active Active
- 2016-04-14 MX MX2017013219A patent/MX381053B/es unknown
- 2016-04-14 SG SG11201707984TA patent/SG11201707984TA/en unknown
- 2016-04-14 NZ NZ735715A patent/NZ735715A/en unknown
- 2016-04-14 AU AU2016248376A patent/AU2016248376B2/en active Active
- 2016-04-14 CA CA2981746A patent/CA2981746C/en active Active
- 2016-04-14 CN CN201680021109.0A patent/CN107531682B/zh active Active
- 2016-04-14 CN CN202110419671.1A patent/CN113307805A/zh active Pending
- 2016-04-14 TW TW105111715A patent/TWI736531B/zh active
- 2016-04-14 KR KR1020247006890A patent/KR20240049684A/ko active Pending
- 2016-04-14 TW TW112101259A patent/TWI832668B/zh active
- 2016-04-14 EA EA201792254A patent/EA035680B1/ru unknown
- 2016-04-14 KR KR1020177033101A patent/KR102643609B1/ko active Active
- 2016-04-14 EP EP22179294.8A patent/EP4119559A1/en active Pending
- 2016-04-14 JP JP2017553956A patent/JP7320741B2/ja active Active
- 2016-04-14 WO PCT/CN2016/079251 patent/WO2016165626A1/en not_active Ceased
- 2016-04-14 TW TW113101605A patent/TWI876835B/zh active
-
2017
- 2017-09-21 ZA ZA2017/06392A patent/ZA201706392B/en unknown
- 2017-11-09 IL IL255555A patent/IL255555B/en unknown
-
2021
- 2021-01-22 JP JP2021009106A patent/JP7383652B2/ja active Active
- 2021-10-31 IL IL287740A patent/IL287740B2/en unknown
-
2023
- 2023-11-08 JP JP2023190552A patent/JP2024012540A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511634A5 (cg-RX-API-DMAC7.html) | ||
| JP2018528199A5 (cg-RX-API-DMAC7.html) | ||
| JP2020033359A5 (cg-RX-API-DMAC7.html) | ||
| AU2016260279B2 (en) | Crystals of azabicyclic compound | |
| TWI826373B (zh) | (s)-2-((2-((s)-4-(二氟甲基)-2-氧代唑烷-3-基)-5,6-二氫苯并[f]咪唑并[1,2-d][1,4]氧氮呯-9-基)胺基)丙醯胺之多晶型及固體形式及製造方法 | |
| JP2013518041A5 (cg-RX-API-DMAC7.html) | ||
| CN107531682A (zh) | B‑raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 | |
| JP2020517611A5 (cg-RX-API-DMAC7.html) | ||
| JP2019515024A (ja) | ボルチオキセチンのパモ酸塩及びその結晶形 | |
| KR102666017B1 (ko) | 엔잘루타미드 결정형의 제조 방법 | |
| CA3009713A1 (en) | Crystalline forms of ponesimod and preparation method thereof | |
| CA3142088A1 (en) | Compound used as kinase inhibitor and application thereof | |
| JP7124035B2 (ja) | アクリジニウム臭化物の製造方法 | |
| AU2018372180B2 (en) | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production | |
| JP6816036B2 (ja) | ヒストン脱アセチル化阻害剤の結晶形態 | |
| JP2013541589A5 (cg-RX-API-DMAC7.html) | ||
| JP6676626B2 (ja) | アシルチオウレア化合物のメシル酸塩の結晶及びその製造方法 | |
| WO2016187028A1 (en) | Heteroaryl compounds, synthesis thereof, and intermediates thereto | |
| ES2727667T3 (es) | Polimorfos de lenalidomida | |
| JP2020530497A (ja) | ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態 | |
| CN111315748B (zh) | 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体 | |
| JP2015521635A5 (cg-RX-API-DMAC7.html) | ||
| CA2561635C (en) | New crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | |
| JPWO2011152411A1 (ja) | チエノピリミジン誘導体の結晶 | |
| JP2010229098A (ja) | イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形 |